Pharming grants SOBI additional territories for the commercialisation of Ruconest®
(Thomson Reuters ONE) -
Leiden, The Netherlands, August 29, 2011. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announces that it has reached mutual
agreement with Esteve to return the rights to market Ruconest® in Spain,
Portugal, Andorra and Greece. SOBI will now take up the exclusive distribution
rights in these countries, extending its territories for Ruconest® to all
European Union countries, Iceland, Norway and Switzerland.
Sijmen de Vries, CEO of Pharming, said "In addition to the new territories in
the Balkans, North Africa and the Middle East announced earlier this month, SOBI
now has exclusive rights for the commercialization of Ruconest® (recombinant
human C1 inhibitor) for the treatment of acute angioedema attacks in patients
with Hereditary Angioedema (HAE) in all European markets where the product has
received market authorization through central European approval. We are
confident that this agreement will optimize the commercial roll-out of
Ruconest®."
About Ruconest (Rhucin) and Hereditary Angioedema
Rhucin® (INN conestat alfa) is a recombinant version of the human protein C1
inhibitor (C1INH). Rhucin® is produced through Pharming's proprietary
technology in milk of transgenic rabbits and in Europe is approved under the
name Ruconest® for treatment of acute angioedema attacks in patients with HAE.
Rhucin® has been granted orphan drug designation in the U.S. for the treatment
of acute attacks of HAE, a genetic disorder in which the patient is deficient in
or lacks a functional plasma protein C1 inhibitor, resulting in unpredictable
and debilitating episodes of intense swelling of the extremities, face, trunk,
genitals, abdomen and upper airway. The frequency and severity of HAE attacks
vary and are most serious when they involve laryngeal edema, which can close the
upper airway and cause death by asphyxiation. According to the U.S. Hereditary
Angioedema Association, epidemiological estimates for HAE range from one in
10,000 to one in 50,000 individuals.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. Ruconest(®) (Rhucin® in non-European territories) is a
recombinant human C1 inhibitor approved for the treatment of angioedema attacks
in patients with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (STO:
SOBI). The product is also under development for follow-on indications, i.e.
antibody-mediated rejection (AMR) and delayed graft function (DGF) following
kidney transplantation. The advanced technologies of the Company include
innovative platforms for the production of protein therapeutics, technology and
processes for the purification and formulation of these products. Additional
information is available on the Pharming website, www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Pharming
Sijmen de Vries, CEO, T: +31 (0)71 52 47 400
Financial Dynamics
Julia Phillips/ John Dineen
Press release (PDF):
http://hugin.info/132866/R/1541784/471796.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1541784]
Unternehmensinformation / Kurzprofil:
Datum: 29.08.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 59848
Anzahl Zeichen: 4467
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming grants SOBI additional territories for the commercialisation of Ruconest®"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
